This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Request a contact

Stay informed

Request a Rep

How Nucala works

Nucala targets IL-5 and is indicated as an add-on treatment for adult, adolescent and paediatric patients (aged 6 or above) with severe refractory eosinophilic asthma.1Nucala is the only anti-IL-5 proven to demonstrate powerful and lasting reduction in exacerbations and OCS dose for up to 4.8  years.234

IL-5 is the major cytokine responsible for the growth, differentiation, recruitment, activation and survival of eosinophils.5

Eosinophils

In severe asthma too many eosinophils may lead to:67

  • More severe asthma symptoms
  • Increased risk of exacerbations

Eosinophils play a role in maintaining health by helping to:58

  • Regulate the immune system
  • Defend the body from pathogens

Nucala is the only anti-IL-5 to demonstrate sustained reduction in blood eosinophils, without complete depletion, for up to 4.8 years.29

See details about Nucala efficacy and safety

See which patients are most likely to benefit from Nucala

IL, interleuken; OCS, oral corticosteroids

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 1

Indication:
Severe Eosinophilic Asthma
NUCALA is indicated as add-on maintenance treatment of severe eosinophilic asthma in patients 6 years and older

Dosage:
Adults and Adolescents (12 years and older)
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.

Children aged 6 to 11 years old:
Children weighing ≥ 40 kg
The recommended dose is 100 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks.

Children weighing < 40 kg
The recommended dose is 40 mg of NUCALA administered by subcutaneous (SC) injection once every 4 weeks

References:

  1. Local Nucala Prescribing Information based on GDS 12
  2. GlaxoSmithKline Data on File REF-26441.
  3. Chupp GL et al. Lancet Respir Med 2017; 5:390-400.
  4. Bel EH et al. N Engl J Med 2014; 371:1189-1197.
  5. Weller PF, Spencer LA. Nat Rev Immunol 2017; 17:746-760.
  6. Price D et al. J Asthma Allergy 2016; 9:1-12.
  7. Garcia G et al. Eur Respir Rev 2013; 22:251-257.
  8. Wen T, Rothenburg ME. Microbiol Spectr 2016; doi: 10.1128/microbiolspec.MCHD-0020-2015.
  9. Khatri S et al. J Allergy Clin Immunol 2019; 143:1742-1751.e7.

Nucala is registered trademark of the GlaxoSmithKline Group of Companies

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs. placebo with the exception of injection site reactions (8% vs. 3%), which occurred mainly within first 3 injections. 1

Trade marks are owned by or licensed to the GSK group of companies.
©2021 GSK group of companies or its licensor.